The eukaryotic translation initiation factor 4E (eIF4E) is dysregulated in a wide variety of cancers. Higher expression of eIF4E promotes tumorigenesis and has been implicated in cancer development and progression. Regulation of eIF4E is particularly controlled through phosphorylation yielding phospho-eIF4E (p-eIF4E). p-eIF4E is a signaling molecule that participate in several pathways, including regulating various cancer-related processes. The role of phosphorylation of eIF4E at Serine 209 on oncogenic transformation has been appreciated for the last 10 years and has been under active investigation as a therapeutic target for cancers including acute myeloid leukemia (AML), but the expression of p-eIF4E in the nucleus and the specific molecular mechanism of action remain largely unresolved. It is selectively and highly expressed in AML where its expression was associated with poor outcomes and prognosis. The purpose of this review is to describe p-eIF4E as an indicator prognosis and a potential anticancer target for biological therapy of AML.

中文翻译：

---

Phospho-eIF4E：急性髓细胞性白血病的新靶标。

真核翻译起始因子4E（eIF4E）在多种癌症中表达失调。eIF4E的较高表达促进肿瘤发生，并与癌症的发生和发展有关。eIF4E的调控尤其是通过磷酸化产生磷酸化eIF4E（p-eIF4E）来控制。p-eIF4E是一种信号分子，参与多种途径，包括调节各种与癌症相关的过程。在过去的10年中，人们认识到eIF4E在209丝氨酸上的磷酸化对致癌性转化的作用，并且作为包括急性髓细胞性白血病（AML）在内的癌症的治疗靶标，正在积极研究中，但是p-eIF4E在细胞核中的表达而且具体的分子作用机理仍未解决。它在AML中选择性且高表达，其表达与不良预后和预后相关。这篇综述的目的是描述p-eIF4E作为AML生物学治疗的指标预后和潜在的抗癌靶标。